



24 July 2020

Federal Communications Commission
445 12th Street SW
Washington, DC 20554

Subject: Limited Agency Agreement
Dermal Photonics Corp.
FCC ID: 2ADZENIRE

To Whom It May Concern:

We, Dermal Photonics Corp., hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number 2ADZENIRE under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is July 24, 2020. The Limited Agency Agreement has no expiration date, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

A handwritten signature in black ink, appearing to read "D. Bean". The signature is fluid and cursive, with a horizontal line extending to the right from the end of the "D".

David Bean
Chief Executive Officer